Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Licenses Merck KGaA Insomnia Agent EMD 281014

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase I 5-HT2a antagonist also has potential for use in other central nervous system disorders, Lilly says. Possible benefits in sleep category include less next-day side effects and use in broad patient population.

You may also be interested in...



Arena Will Move 5-HT2A Antagonist Into Phase III For Insomnia In 2008

Phase II data show that APD125 significantly improves sleep maintenance in chronic insomnia patients.

Arena Will Move 5-HT2A Antagonist Into Phase III For Insomnia In 2008

Phase II data show that APD125 significantly improves sleep maintenance in chronic insomnia patients.

Pfizer/Neurocrine File First Indiplon NDA With Eye On Q4 2005 Launch

The first of two NDA filings for Pfizer/Neurocrine's insomnia agent indiplon puts the drug on track for a launch in the fourth quarter of 2005

Topics

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel